DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)
South Korea · Delayed Price · Currency is KRW 22,750
+600 (2.71%)
Oct 2, 2026, 3:30 PM KST
DongKook Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,026,269 | 767,269 | 726,357 | 710,431 | 729,658 | 958,073 | |
Market Cap Growth | 22.45% | 5.63% | 2.24% | -2.63% | -23.84% | -25.47% |
Enterprise Value | 1,075,994 | 823,082 | 792,360 | 751,610 | 743,265 | 932,778 |
Last Close Price | 22750.00 | 17150.00 | 16330.33 | 15783.38 | 16031.86 | 20834.20 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 13.40 | 11.62 | 11.95 | 15.19 | 13.79 | 19.03 |
Forward PE | 11.55 | 9.87 | 11.01 | 11.66 | 11.64 | 15.82 |
PS Ratio | 1.05 | 0.83 | 0.89 | 0.97 | 1.10 | 1.61 |
PB Ratio | 1.29 | 1.00 | 1.07 | 1.18 | 1.31 | 1.90 |
P/TBV Ratio | 1.54 | 1.22 | 1.27 | 1.33 | 1.48 | 2.14 |
P/FCF Ratio | 30.70 | 29.46 | 14.88 | 93.28 | - | - |
P/OCF Ratio | 11.43 | 11.16 | 9.55 | 17.00 | 17.84 | 21.46 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.10 | 0.89 | 0.98 | 1.03 | 1.12 | 1.57 |
EV/EBITDA Ratio | 7.97 | 6.42 | 7.32 | 8.54 | 8.02 | 11.58 |
EV/EBIT Ratio | 10.60 | 8.53 | 9.92 | 11.24 | 10.11 | 14.76 |
EV/FCF Ratio | 32.19 | 31.60 | 16.24 | 98.69 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.10 | 0.12 | 0.13 | 0.12 | 0.19 |
Debt / EBITDA Ratio | 0.49 | 0.59 | 0.74 | 0.87 | 0.72 | 1.22 |
Debt / FCF Ratio | 2.01 | 2.93 | 1.65 | 10.07 | - | - |
Net Debt / Equity Ratio | -0.06 | -0.07 | -0.01 | -0.03 | -0.07 | -0.14 |
Net Debt / EBITDA Ratio | -0.38 | -0.40 | -0.09 | -0.20 | -0.44 | -0.89 |
Net Debt / FCF Ratio | -1.53 | -1.95 | -0.21 | -2.29 | 5.82 | 11.34 |
Asset Turnover | 0.93 | 0.92 | 0.91 | 0.91 | 0.87 | 0.84 |
Inventory Turnover | 2.39 | 2.54 | 2.45 | 2.48 | 2.53 | 2.69 |
Quick Ratio | 1.31 | 1.39 | 1.26 | 1.34 | 1.49 | 1.40 |
Current Ratio | 2.05 | 2.11 | 2.02 | 2.06 | 2.22 | 1.91 |
Return on Equity (ROE) | 10.72% | 10.25% | 9.72% | 8.42% | 10.33% | 11.03% |
Return on Assets (ROA) | 6.06% | 5.98% | 5.57% | 5.20% | 6.05% | 5.59% |
Return on Invested Capital (ROIC) | 11.30% | 11.15% | 9.36% | 9.75% | 12.39% | 12.30% |
Return on Capital Employed (ROCE) | 12.30% | 12.10% | 11.10% | 10.50% | 12.40% | 11.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 7.45% | 8.61% | 8.43% | 6.64% | 7.25% | 5.25% |
FCF Yield | 3.26% | 3.40% | 6.72% | 1.07% | -0.96% | -0.66% |
Dividend Yield | 0.88% | 1.17% | - | - | - | - |
Payout Ratio | 11.82% | 14.00% | 13.58% | 17.07% | 15.22% | 15.99% |
Buyback Yield / Dilution | -0.46% | -0.05% | -0.01% | -0.02% | -0.01% | - |
Total Shareholder Return | 0.42% | 1.12% | -0.01% | -0.02% | -0.01% | - |